These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9466519)

  • 1. thy/liv-SCID-hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues.
    Pettoello-Mantovani M; Kollmann TR; Katopodis NF; Raker C; Kim A; Yurasov S; Wiltshire H; Goldstein H
    J Infect Dis; 1998 Feb; 177(2):337-46. PubMed ID: 9466519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues.
    Pettoello-Mantovani M; Kollmann TR; Raker C; Kim A; Yurasov S; Tudor R; Wiltshire H; Goldstein H
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1880-7. PubMed ID: 9303378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver.
    Kollmann TR; Pettoello-Mantovani M; Katopodis NF; Hachamovitch M; Rubinstein A; Kim A; Goldstein H
    Proc Natl Acad Sci U S A; 1996 Apr; 93(7):3126-31. PubMed ID: 8610180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1.
    Kollmann TR; Pettoello-Mantovani M; Zhuang X; Kim A; Hachamovitch M; Smarnworawong P; Rubinstein A; Goldstein H
    J Exp Med; 1994 Feb; 179(2):513-22. PubMed ID: 8294863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice.
    Kollmann TR; Kim A; Pettoello-Mantovani M; Hachamovitch M; Rubinstein A; Goldstein MM; Goldstein H
    J Immunol; 1995 Jan; 154(2):907-21. PubMed ID: 7814892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model.
    Honeycutt JB; Wahl A; Archin N; Choudhary S; Margolis D; Garcia JV
    Retrovirology; 2013 Oct; 10():121. PubMed ID: 24156277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.
    Stoddart CA; Bales CA; Bare JC; Chkhenkeli G; Galkina SA; Kinkade AN; Moreno ME; Rivera JM; Ronquillo RE; Sloan B; Black PL
    PLoS One; 2007 Aug; 2(7):e655. PubMed ID: 17668043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.
    Kravcik S; Gallicano K; Roth V; Cassol S; Hawley-Foss N; Badley A; Cameron DW
    J Acquir Immune Defic Syndr; 1999 Aug; 21(5):371-5. PubMed ID: 10458617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SCID-hu mice: a model for studying disseminated HIV infection.
    Goldstein H; Pettoello-Mantovani M; Katopodis NF; Kim A; Yurasov S; Kollmann TR
    Semin Immunol; 1996 Aug; 8(4):223-31. PubMed ID: 8883145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
    Markowitz M; Vesanen M; Tenner-Racz K; Cao Y; Binley JM; Talal A; Hurley A; Jin X; Chaudhry MR; Yaman M; Frankel S; Heath-Chiozzi M; Leonard JM; Moore JP; Racz P; Nixon DF; Ho DD
    J Infect Dis; 1999 Mar; 179(3):527-37. PubMed ID: 9952358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a novel transgenic mouse/SCID-hu mouse system to characterize the in vivo behavior of reservoirs of human immunodeficiency virus type 1-infected cells.
    Wang EJ; Pettoello-Mantovani M; Anderson CM; Osiecki K; Moskowitz D; Goldstein H
    J Infect Dis; 2002 Nov; 186(10):1412-21. PubMed ID: 12404156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
    Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice.
    Stoddart CA; Moreno ME; Linquist-Stepps VD; Bare C; Bogan MR; Gobbi A; Buckheit RW; Bedard J; Rando RF; McCune JM
    Antimicrob Agents Chemother; 2000 Mar; 44(3):783-6. PubMed ID: 10681360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue.
    Goldstein H; Pettoello-Mantovani M; Anderson CM; Cordelier P; Pomerantz RJ; Strayer DS
    J Infect Dis; 2002 May; 185(10):1425-30. PubMed ID: 11992277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
    Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T
    J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
    J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus.
    Stoddart CA; Liegler TJ; Mammano F; Linquist-Stepps VD; Hayden MS; Deeks SG; Grant RM; Clavel F; McCune JM
    Nat Med; 2001 Jun; 7(6):712-8. PubMed ID: 11385509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.